Key takeaways:
- Fermentation-derived peptides are moving into bars, bakery items and supplements, but the science hasn’t quite caught up with the hype
- GLP-1 drugs have boosted interest in satiety and protein, but functional foods can’t be marketed as drug-like weight-loss alternatives
- Bitterness, stability and unclear regulation remain the biggest hurdles to mainstream adoption
Fermentation-derived peptides are starting to turn up in protein products and early-stage bakery and snack formulations, as manufacturers test whether they can deliver a genuine functional benefit rather than simply riding the GLP-1 wave.
Some believe they could eventually do for the snack aisle what semaglutide has done for pharmacy sales, though whether that’s realistic is a question the food and beverage industry is only starting to work through, and the answer depends heavily on who you ask.
Peptides: A quick explainer
What exactly is a peptide? A short chain of amino acids, the same building blocks that make up larger proteins. It’s a broad family: both the GLP-1 drugs behind the current wave of interest – semaglutide, tirzepatide and liraglutide – and the ingredients explored below are technically peptides.
So are they related? Only in the loosest sense – cousins, not siblings. GLP-1 drugs are synthetic, pharmaceutical-grade peptides, typically injected, engineered to trigger a specific hormonal response that suppresses appetite. Fermentation-derived peptides are a separate, food-grade branch of the same family, occurring when a larger protein – from dairy, soy, grain or another source – is broken down through fermentation or enzymatic hydrolysis. They aren’t designed to mimic GLP-1 drugs and don’t act on the same receptors.
So why does GLP-1 matter to them at all? Because of what the drugs have done to consumer attention, not any shared mechanism. Ozempic and its rivals have made millions of people newly interested in satiety, protein quality and metabolic health, and manufacturers are exploring whether fermentation-derived peptides can support those same goals through diet rather than medicine.
What do they actually do in food? Depending on the specific peptide, they may offer antimicrobial or antioxidant activity that extends shelf life, support protein digestibility, or contribute to clean label positioning. None of this is guaranteed: each benefit has to be proven for the specific ingredient and food matrix, rather than assumed for peptides as a category.
Where the evidence actually stands
Dr Kantha Shelke, food scientist and principal at Corvus Blue and a senior lecturer at Johns Hopkins University, doesn’t sugarcoat the gap between enthusiasm and proof.
Asked whether the excitement around fermentation-derived peptides is justified, she says: “The interest is justified but the expectations are out of sync. These peptides tend to be developed by enthusiastic biochemists who treat them as plug-and-play and think if one ingests the compound or adds it to a formulation, one can see the desired effect. Human physiology is far less accommodating.
“Swallowing something is no guarantee it reaches the intended destination, slots neatly into a pathway, and produces the change we want,” she adds. “It is not that simple.”
Stomach acid and digestive enzymes routinely degrade peptides before they reach the bloodstream, and while encapsulation can improve stability, it “will only work if it releases the payload at the right time, in the right place, along the digestive journey or in the process of making a food.” Getting that timing and targeting right, “is the hard part”.
Dr Shelke points to food-safety literature on fermented-food-derived antimicrobial peptides that reaches a similar conclusion: these compounds are promising, but real-world translation is held back by instability, interference from the food matrix and limited validation, a dynamic the research describes as a ‘stability-potency paradox’.
Peptides that look active in a test tube “can lose function under gastrointestinal, food-matrix or storage conditions” and much of the underlying research is built on shaky foundations, with inconsistent standardisation and real difficulty distinguishing a genuinely active peptide from a degradation fragment. Her verdict: “A promising toolbox? Yes. But the gap between laboratory activity and delivered benefit is still wide.”
Formulators across food and beverage – bakery and snacks especially – have good reason to pay attention.
Bioactive peptides sit between whole proteins and free amino acids, and are short chains released through fermentation or enzymatic hydrolysis – “short enough to be absorbed, specific enough to carry a targeted biological signal” says Dr Shelke. Unlike probiotics, which are live organisms, peptides are molecules, “so they behave very differently under processing”, which is part of their appeal: some tolerate heat well enough to survive baking or extrusion, conditions that kill most probiotics outright, and their antimicrobial and antioxidant activity may help extend shelf life.
Dr Shelke adds a caveat to every one of those points. “Each depends heavily on the specific peptide, not the category as a whole.”
Manufacturers, she adds, “should see the real potential, but also understand that each benefit also must be demonstrated for the specific peptide and the specific matrix. They do not apply across the category.”
A ripple effect well beyond weight loss
Caitlin Koppenhaver, chief industry advisor at the American Peptide Association, notes the GLP-1 boom has reshaped the wider conversation around peptides.
“The GLP-1 conversation has accelerated further interest in satiety, protein quality, muscle maintenance, metabolic health and nutrient-dense formulations,” she says, adding the story isn’t simply about consumers eating less.
GLP-1 medicines, she notes, are generally used alongside – not instead of – diet, physical activity and broader lifestyle change, and clinical guidance has flagged nutritional deficiencies, muscle loss and bone loss as real risks to manage during therapy.
The pharma side of that story is moving fast, too. The FDA has proposed permanently excluding three GLP-1 drugs from a list that lets pharmacies compound cheaper versions of medicines such as Ozempic, with a decision due after an extended comment period closing 30 July. The ruling sits entirely outside food and beverage regulation, but it’s a reminder of just how much scrutiny peptides now attract.
That creates an opportunity for the food and beverage industry, but also a firm boundary. “Functional foods should not be positioned as drug-like GLP-1 alternatives or as products that treat obesity, diabetes or other disease states,” says Koppenhaver. Fermentation-derived peptides could genuinely fit, in her view, by supporting those same goals of satiety, protein quality and metabolic wellness through everyday formulations, “particularly where they can be responsibly developed for consistency, stability, taste, digestibility, or targeted nutritional functionality”.
She’s candid that the underlying science still has ground to cover. A 2025 review in Food Chemistry found that bioactive peptides from fermented foods show promise as functional foods or nutraceuticals, but their bioavailability and efficacy vary across populations depending on genetics, gut microbiota and diet.
Koppenhaver identifies classification as the first real hurdle: deciding whether an ingredient counts as a conventional food ingredient, a dietary supplement ingredient, or something else, since that choice determines whether it needs GRAS status, food additive authorisation, or a new dietary ingredient notification.
Marketing claims demand just as much discipline.
“Food manufacturers should avoid crossing from permissible nutrition or structure/function-type claims into disease-treatment, weight-loss drug, or GLP-1-like claims,” she says.
Her overall assessment is that expectations may be running ahead of the regulatory framework for now, though she believes fermentation-derived peptides can become part of the next generation of functional ingredients “if the industry builds the category carefully”.
From the formulation bench to the shelf
Brian Upton, co-founder of gut-health brand Elevate Organic, has already put fermentation-derived peptides into three probiotic supplement formulas. He sees this less as a hunt for a single new hero ingredient, and more part of a much older fermentation story.
“Fermentation has been supporting human health for thousands of years, but we’re just starting to understand all of the beneficial compounds it produces, including peptides. As consumers become more interested in probiotics, postbiotics and gut health, peptides help expand that conversation.”
Upton acknowledges the technical hurdles – stability, taste, manufacturing – but argues the bigger barrier is education. “Most consumers don’t understand fermentation or realise how closely digestive health is connected to overall health,” he says. “At the end of the day, people buy foods because they taste good and fit their lifestyle.”
He believes fermentation-derived peptides will begin popping up more prominently in multiple applications, notably protein bars, meal-replacement products, ready-to-drink beverages, better-for-you bars, high-protein crackers and chips, since consumers already look to those products for more than flavour.
That formulation work is on show this week at IFT FIRST 2026 in Chicago, where peptide biotech Nuritas is exhibiting a portfolio of plant-based peptide hydrolysates built specifically for food manufacturing.
That formulation work is already on show at IFT FIRST 2026 in Chicago this week, where peptide biotech Nuritas is exhibiting plant-based peptide hydrolysates built specifically for food manufacturing rather than supplement delivery. The company says its ingredients have held up through retort and UHT beverage processing, with potential uses spanning frozen yogurt, ready-to-drink beverages, savoury snacks and bakery formats.
“Functional benefits do not have to be confined to capsules or powder blends,” says Dr Nora Khaldi, Nuritas’ chief executive and founder.
Its fava bean-derived peptide shows Koppenhaver’s classification hurdle being cleared in practice: the FDA issued a letter of no objection confirming its GRAS status in December 2024, and the company says it also carries non-novel food status in Canada and the EU. That’s one ingredient clearing one regulatory bar, though, not proof the wider classification question is settled for the category as a whole.
These conversations sketch a category with real momentum but no shortage of unresolved questions.
Bitterness still needs masking; stability still needs proving in the finished product rather than the lab; and regulators on both sides of the Atlantic are still working out exactly where these ingredients belong.
Nobody here is arguing that fermentation-derived peptides can replace a GLP-1 prescription. Done carefully, though, they might earn a genuine place in the industry’s next wave of functional formulation.
Study:
Brijesh B, Kunal MG, et al. Production, characterization and bio-functional properties of multi-functional peptides from fermented plant-based foods: A review. Food Bioscience, Volume 64, 2025, 105877, ISSN 2212-4292. https://doi.org/10.1016/j.fbio.2025.105877
Bruce BB, Boateng ID, Boateng C. Recent advances in bioactive peptides from fermented plant-based foods and their bioactivities. Food Chem X. 2025 Nov 14;32:103291. https://doi:10.1016/j.fochx.2025.103291. PMID: 41362319; PMCID: PMC12682144.
